Compare AN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AN | ADPT |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.5B |
| IPO Year | 1995 | 2019 |
| Metric | AN | ADPT |
|---|---|---|
| Price | $155.41 | $26.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $233.33 | $28.31 |
| AVG Volume (30 Days) | 621.9K | ★ 2.3M |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.71 | ★ 63.89 |
| EPS | ★ 11.26 | N/A |
| Revenue | ★ $27,631,400,000.00 | $276,976,000.00 |
| Revenue This Year | $0.41 | $5.94 |
| Revenue Next Year | $3.53 | $22.42 |
| P/E Ratio | $14.02 | ★ N/A |
| Revenue Growth | 3.24 | ★ 54.77 |
| 52 Week Low | $153.46 | $12.00 |
| 52 Week High | $235.81 | $30.74 |
| Indicator | AN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 46.85 |
| Support Level | N/A | $23.73 |
| Resistance Level | $213.29 | $26.51 |
| Average True Range (ATR) | 8.01 | 1.44 |
| MACD | -1.01 | -0.26 |
| Stochastic Oscillator | 4.25 | 9.13 |
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 245 dealerships, plus 52 collision centers. The firm also has 24 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which proved to be a smart move.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.